{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:28Z","timestamp":1794047428372,"version":"4.8.0"},"reference-count":47,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Hematotoxicity is the most common long-term adverse event (AE) after chimeric antigen receptor T-cell (CAR T) therapy. However, patients who receive CAR T therapy in pivotal clinical trials are subjected to restrictive selection criteria, and this means that rare but fatal toxicities are underestimated. Here, we systematically analyzed CAR T-associated hematologic AE using the US Food and Drug Administration Adverse Event Reporting System (FAERS) between January 2017 and December 2021. Disproportionality analyses were performed using reporting odds ratios (ROR) and information component (IC); the lower limit of the ROR and IC 95% confidence interval (CI) (ROR025 and IC025) exceeding one and zero was considered significant, respectively. Among the 105,087,611 reports in FAERS, 5,112 CAR T-related hematotoxicity reports were identified. We found 23 significant over-reporting hematologic AE (ROR025 &gt;1) compared to the full database, of which hemophagocytic lymphohistiocytosis (HLH; n=136 [2.7%], ROR025 = 21.06), coagulopathy (n=128 [2.5%], ROR025 = 10.43), bone marrow failure (n=112 [2.2%], ROR025 = 4.88), disseminated intravascular coagulation (DIC; n=99 [1.9%], ROR025 = 9.64), and B-cell aplasia (n=98 [1.9%], ROR025 = 118.16, all IC025 &gt; 0) were highly under-reported AE in clinical trials. Importantly, HLH and DIC led to mortality rates of 69.9% and 59.6%, respectively. Lastly, hematotoxicity-related mortality was 41.43%, and 22 death-related hematologic AE were identified using LASSO regression analysis. These findings could help clinicians in the early detection of those rarely reported but lethal hematologic AE, thus reducing the risk of severe toxicities for CAR T recipients.<\/jats:p>","DOI":"10.3324\/haematol.2022.281455","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T03:43:37Z","timestamp":1676519017000},"page":"2067-2079","source":"Crossref","is-referenced-by-count":29,"title":["Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy"],"prefix":"10.3324","volume":"108","author":[{"given":"Zhiqiang","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyuan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gusheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongguang","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"50263","doi-asserted-by":"crossref","unstructured":"Shah NN, Lee DW, Yates B. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021; 39(15):1650-1659.","DOI":"10.1200\/JCO.20.02262"},{"key":"50264","doi-asserted-by":"crossref","unstructured":"Nastoupil LJ, Jain MD, Feng L. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38(27):3119-3128.","DOI":"10.1200\/JCO.19.02104"},{"key":"50265","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"50266","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20(1):31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"50267","doi-asserted-by":"crossref","unstructured":"Frey NV, Shaw PA, Hexner EO. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2020; 38(5):415-422.","DOI":"10.1200\/JCO.19.01892"},{"key":"50268","doi-asserted-by":"crossref","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019; 25(4):e123-e127.","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"50269","doi-asserted-by":"crossref","unstructured":"Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019; 94(S1):S42-S49.","DOI":"10.1002\/ajh.25445"},{"key":"50270","doi-asserted-by":"crossref","unstructured":"Wudhikarn K, Pennisi M, Garcia-Recio M. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020; 4(13):3024-3033.","DOI":"10.1182\/bloodadvances.2020001972"},{"key":"50271","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Sesques P. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021; 138(24):2499-2513.","DOI":"10.1182\/blood.2020010543"},{"key":"50272","doi-asserted-by":"crossref","unstructured":"Fried S, Avigdor A, Bielorai B. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650.","DOI":"10.1038\/s41409-019-0487-3"},{"key":"50273","doi-asserted-by":"crossref","unstructured":"Nahas GR, Komanduri KV, Pereira D. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020; 61(4):940-943.","DOI":"10.1080\/10428194.2019.1697814"},{"key":"50274","doi-asserted-by":"crossref","unstructured":"Sesques P, Ferrant E, Safar V. Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020; 95(11):1324-1333.","DOI":"10.1002\/ajh.25951"},{"key":"50275","doi-asserted-by":"crossref","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020; 26(1):26-33.","DOI":"10.1016\/j.bbmt.2019.08.003"},{"key":"50276","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1):45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"50277","doi-asserted-by":"crossref","unstructured":"Ang PS, Chen Z, Chan CL. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. Expert Opin Drug Saf. 2016; 15(5):583-590.","DOI":"10.1517\/14740338.2016.1167184"},{"key":"50278","doi-asserted-by":"crossref","unstructured":"Hou Y, Ye X, Wu G. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Expert Opin Drug Saf. 2014; 13(7):853-857.","DOI":"10.1517\/14740338.2014.915938"},{"key":"50279","doi-asserted-by":"crossref","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013; 22(1):57-69.","DOI":"10.1177\/0962280211403604"},{"key":"50280","doi-asserted-by":"crossref","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999; 20(2):109-117.","DOI":"10.2165\/00002018-199920020-00002"},{"key":"50281","doi-asserted-by":"crossref","unstructured":"Saez-Iba\u00f1ez AR, Upadhaya S, Partridge T. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov. 2022; 21(9):631-632.","DOI":"10.1038\/d41573-022-00095-1"},{"key":"50282","doi-asserted-by":"crossref","unstructured":"Luo W, Li C, Zhang Y. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis. BMC Cancer. 2022; 22(1):98.","DOI":"10.1186\/s12885-021-09102-x"},{"key":"50283","doi-asserted-by":"crossref","unstructured":"Westin JR, Kersten MJ, Salles G. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021; 96(10):1295-1312.","DOI":"10.1002\/ajh.26301"},{"key":"50284","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Chavez JC, Sehgal AR. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022; 23(1):91-103.","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"50285","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"50286","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Tam CS, Borchmann P. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22(10):1403-1415.","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"50287","doi-asserted-by":"crossref","unstructured":"Sandler RD, Tattersall RS, Schoemans H. Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020; 11:524.","DOI":"10.3389\/fimmu.2020.00524"},{"key":"50288","doi-asserted-by":"crossref","unstructured":"Cutini I, Puccini B, Fabbri A. Late haemophagocytic lymphohistiocytosis in a patient treated with axicabtagene ciloleucel. Transpl Immunol. 2022; 75:101719.","DOI":"10.1016\/j.trim.2022.101719"},{"key":"50289","doi-asserted-by":"crossref","unstructured":"Wang Y, Qi K, Cheng H. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transplant. 2020; 26(5):865-875.","DOI":"10.1016\/j.bbmt.2019.11.027"},{"key":"50290","doi-asserted-by":"crossref","unstructured":"Yan Z, Zhang H, Cao J. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol. 2021; 12:611366.","DOI":"10.3389\/fimmu.2021.611366"},{"key":"50291","doi-asserted-by":"crossref","unstructured":"Johnsrud A, Craig J, Baird J. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv. 2021; 5(21):4465-4475.","DOI":"10.1182\/bloodadvances.2021004716"},{"key":"50292","doi-asserted-by":"crossref","unstructured":"Jiang H, Liu L, Guo T. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019; 98(7):1721-1732.","DOI":"10.1007\/s00277-019-03685-z"},{"key":"50293","doi-asserted-by":"crossref","unstructured":"Strati P, Varma A, Adkins S. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021; 106(10):2667-2672.","DOI":"10.3324\/haematol.2020.254045"},{"key":"50294","doi-asserted-by":"crossref","unstructured":"Haidar G, Dorritie K, Farah R. Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis. Clin Infect Dis. 2020; 71(3):672-676.","DOI":"10.1093\/cid\/ciz1127"},{"key":"50295","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Wulf GG, Duell J. Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA\/DRST study. Blood Adv. 2023; 7(4):555-559.","DOI":"10.1182\/bloodadvances.2022008042"},{"key":"50296","doi-asserted-by":"crossref","unstructured":"Tesi B, Lagerstedt-Robinson K, Chiang SCC. Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis. Genome Med. 2015; 7:130.","DOI":"10.1186\/s13073-015-0244-1"},{"key":"50297","doi-asserted-by":"crossref","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021; 21(3):145-161.","DOI":"10.1038\/s41568-020-00323-z"},{"key":"50298","doi-asserted-by":"crossref","unstructured":"Jain T, Knezevic A, Pennisi M. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4(15):3776-3787.","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"50299","doi-asserted-by":"crossref","unstructured":"Goldman A, Maor E, Bomze D. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol. 2021; 78(18):1800-1813.","DOI":"10.1016\/j.jacc.2021.08.044"},{"key":"50300","doi-asserted-by":"crossref","unstructured":"Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne). 2018; 9:788.","DOI":"10.3389\/fendo.2018.00788"},{"key":"50301","doi-asserted-by":"crossref","unstructured":"Tie R, Li H, Cai S. Interleukin-6 signaling regulates hematopoietic stem cell emergence. Exp Mol Med. 2019; 51(10):1-12.","DOI":"10.1038\/s12276-019-0320-5"},{"key":"50302","doi-asserted-by":"crossref","unstructured":"de Bruin AM, Demirel \u00d6, Hooibrink B. Interferon-\u03b3 impairs proliferation of hematopoietic stem cells in mice. Blood. 2013; 121(18):3578-3585.","DOI":"10.1182\/blood-2012-05-432906"},{"key":"50303","doi-asserted-by":"crossref","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019; 34:45-55.","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"50304","doi-asserted-by":"crossref","unstructured":"Gust J, Hay KA, Hanafi L-A. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017; 7(12):1404-1419.","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"50305","doi-asserted-by":"crossref","unstructured":"Grupp SA, Kalos M, Barrett D. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518.","DOI":"10.1056\/NEJMoa1215134"},{"key":"50306","doi-asserted-by":"crossref","unstructured":"Maude SL, Frey N, Shaw PA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-1517.","DOI":"10.1056\/NEJMoa1407222"},{"key":"50307","doi-asserted-by":"crossref","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020; 146(5):940-948.","DOI":"10.1016\/j.jaci.2020.07.025"},{"key":"50308","doi-asserted-by":"crossref","unstructured":"Pasquini MC, Hu Z-H, Curran K. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020; 4(21):5414-5424.","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"50309","doi-asserted-by":"crossref","unstructured":"Buechner J, Grupp SA, Hiramatsu H. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021; 5(2):593-601.","DOI":"10.1182\/bloodadvances.2020002757"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281455\/75346","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281455\/75872","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10978\/75346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:32Z","timestamp":1794045812000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281455","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}